NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: STAR · data 2026-10-30
Strides Pharma Science Ltd
In plain words
Price: 15.2% below its 52-week high of ₹1,260.9.
Delivery: 49.3% of traded shares were kept for delivery over the last 10 sessions, against 47.4% over the last 60.
Latest results: a net profit of ₹131 cr for the quarter ended Sept 2026 (+2.6% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹5,004 cr |
| Net profit (last 12 months) | ₹614 cr |
| Sales growth, 3 years (yearly) | 9.2% |
| Profit growth, 3 years (yearly) | — |
Latest results in brief (Q2 FY27)
STAR Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹1,429.73 crore, up 17.1% YoY and up 13% QoQ.
Net profit was ₹130.84 crore, up 2.6% YoY and down 16.6% QoQ.
Operating margin was 17.5% (19% a year ago).
EPS was ₹14.19, up 2.5% YoY and down 16.6% QoQ.
STAR के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹1,429.73 करोड़; पिछले साल की तुलना में 17.1% की बढ़त, पिछली तिमाही की तुलना में 13% की बढ़त।
शुद्ध मुनाफ़ा: ₹130.84 करोड़; पिछले साल की तुलना में 2.6% की बढ़त, पिछली तिमाही की तुलना में 16.6% की गिरावट।
ऑपरेटिंग मार्जिन: 17.5% (एक साल पहले 19%)।
EPS: ₹14.19; पिछले साल की तुलना में 2.5% की बढ़त, पिछली तिमाही की तुलना में 16.6% की गिरावट।
STARના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹1,429.73 કરોડ; ગયા વર્ષની સરખામણીએ 17.1% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 13% વધારો.
ચોખ્ખો નફો: ₹130.84 કરોડ; ગયા વર્ષની સરખામણીએ 2.6% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 16.6% ઘટાડો.
ઓપરેટિંગ માર્જિન: 17.5% (એક વર્ષ પહેલાં 19%).
EPS: ₹14.19; ગયા વર્ષની સરખામણીએ 2.5% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 16.6% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
52/100 · Building over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 22/30: Delivery 50.5% over the last 20 sessions vs 34.9% in the 40 before (1.45x); shares delivered per day 1.27x usual; 2 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 17/20: Net +₹69.24 cr bought in bulk/block deals over 90 days (1.68x a usual day's traded value); 1 net buying day, 0 net selling days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 8/15: Verdict "Building", sustained score 42/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Deal ● Results ● Dividend
- 30 Oct 26Deal Bulk deal: SBI LIFE INSURANCE COMPANY LIMITED bought ₹69.24 cr
- 29 Oct 26Results Q2 FY27 results: profit +2.6% YoY -1.5% next session
- 31 Jul 26Results Q1 FY27 results: profit +57.5% YoY -4.1% next session
- 31 Jul 26Dividend Dividend ₹5 (ex-date) -4.1% next session
- 13 Jul 26Results Q4 FY26 results: profit +54.4% YoY -1.1% next session
- 30 Jan 26Results Q3 FY26 results: profit +129.8% YoY +6.5% next session
- 31 Oct 25Results Q2 FY26 results: profit +36.8% YoY +15.5% next session
- 29 Jul 25Results Q1 FY26 results: profit +41.9% YoY +2.5% next session
- 22 Jul 25Dividend Dividend ₹4 (ex-date) +3.4% next session
- 22 May 25Results Q4 FY25 results: profit +352.1% YoY +5.2% next session
- 30 Jan 25Results Q3 FY25 results: profit +77.1% YoY +12.6% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹1,430 cr | ₹131 cr | +2.6% | 17.5% | 14.19 |
| Jun 2026 | ₹1,265 cr | ₹157 cr | +57.5% | 18.2% | 17.02 |
| Mar 2026 | ₹1,323 cr | ₹127 cr | +54.4% | 18.1% | 13.77 |
| Dec 2025 | ₹1,195 cr | ₹202 cr | +129.8% | 19.8% | 21.93 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 29.00% | 27.91% | 27.91% | 27.86% |
| Foreign institutions (FII) | 27.98% | 28.39% | 28.68% | 29.52% |
| Domestic institutions (DII) | 15.51% | 15.41% | 14.45% | 13.02% |
| Mutual funds | 10.31% | 8.73% | 8.56% | 8.59% |
| Retail investors | 12.70% | 12.89% | 12.66% | 12.81% |
| Number of shareholders | 93,336 | 94,850 | 86,616 | 85,589 |
Common questions
What was Strides Pharma Science Ltd's latest quarterly profit?
Strides Pharma Science Ltd reported a net profit of ₹131 cr for the quarter ended Sept 2026 (+2.6% on the same quarter a year earlier), on revenue of ₹1,430 cr.
How much do promoters hold in Strides Pharma Science Ltd?
Promoters held 29.00% of Strides Pharma Science Ltd at the end of Sept 2026, with 33.79% of promoter shares pledged.
Is Strides Pharma Science Ltd debt-free?
Its latest reported debt-to-equity ratio is 0.57.
What is Strides Pharma Science Ltd's P/E ratio?
About 16.1, based on the last 12 months' earnings and a price of ₹1,068.8 (data 2026-10-30).
What is the 52-week high and low of Strides Pharma Science Ltd?
The 52-week high is ₹1,260.9 and the 52-week low is ₹768.65.
Mutual funds holding Strides Pharma Science Ltd
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 1 scheme holding about ₹37 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| ADITYA BIRLA SUN LIFE VALUE FUND | Aditya Birla Sun Life Mutual Fund | 0.55% | ₹37 cr |
Similar companies
Viyash Scientific Limited (VIYASH) · Blue Jet Healthcare Limited (BLUEJET) · Procter & Gamble Health Ltd. (PGHL) · Aarti Pharmalabs Limited (AARTIPHARM) · Symbiotec Pharmalab Limited (SYMBIOTEC)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open STAR in NSE Scanner →